Datamonitor's October edition of the Cancer Review brings you the latest news, expert analysis and research in the cancer industry.

It covers all the major current business issues and events, including R&D, licensing deals, alliances and joint ventures, and regulatory decisions.

Scope

• Strategic insight into the future shape of cancer companies and markets

• The most significant cancer industry news compiled into one monthly update

• Expert analysis into the implications of the month's important cancer industry events

• Insight into the future shape of the market for players at all levels

• All the month's cancer stories in headline and summary form

Report Highlights

Out of the dozens of topics covered in this month's review, the most important include:

* Novartis's Gleevec was granted a priority review by the FDA for possible use as a first-line treatment for newly diagnosed patients with Philadelphia-chromosome positive chronic myeloid leukemia in the chronic phase, the earliest stage of the disease.

* A US District Court jury found unanimously in favor of Genentech following the claims of Chiron's that Genentech had infringed a patent with their metastatic breast cancer drug, Herceptin.

Reasons to Purchase

• Not only keeps you updated about industry events - it also gives you opinion and insight

• Draws upon Datamonitor analysts' extensive experience to bring you our perspective on the impact of the latest events

• Provides you with your own news archive to track company and industry progress, giving you an extensive reference to relevant events and issues

R&D UPDATE: BREAST CANCER

The most significant news in breast cancer R&D, compiled into one monthly update.

R&D UPDATE: LUNG CANCER

The most significant news in lung cancer R&D, compiled into one monthly update.

R&D UPDATE: PROSTATE CANCER

The most significant news in prostate cancer R&D, compiled into one monthly update.

R&D UPDATE: COLORECTAL CANCER

The most significant news in colorectal cancer R&D, compiled into one monthly update.

R&D UPDATE: OTHER CANCERS

The most significant news in other cancers, compiled into one monthly update including:

• Lymphoma and leukemia

• Brain cancer

• Ovarian cancer

• Liver cancers

LATEST COMMENT

Expert analysis of the implications of the month's important industry events

• Novartis: multiple roles for Gleevec

• AstraZeneca: a nail in the coffin of EGFr inhibitor hopes

• Novuspharma: lending a hand to Micromet

• Chiron/Genentech: battling on despite Herceptin ruling

MARKET SNAPSHOTS

Insight into the future shape of the market for players at all levels

• Tumors: breast most common in 2001

• Malignant melanoma: incidence to hit 77,000 in 2010

NEWS HEADLINES - BREAST CANCER

All the month's breast cancer news stories in headline and summary form

NEWS HEADLINES - LUNG CANCER

All the month's lung cancer news stories in headline and summary form

NEWS HEADLINES - PROSTATE CANCER

All the month's prostate cancer news stories in headline and summary form

NEWS HEADLINES - COLORECTAL CANCER

All the month's colorectal cancer news stories in headline and summary form

NEWS HEADLINES - OTHER CANCERS

All the month's other cancer news stories in headline and summary form

To order - click here!